Related Experiment Video
Updated: Jun 9, 2025
06:03
Isolation and Characterization of Microvesicles from Peripheral Blood
Published on: January 6, 2017
23.0K
Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk
Valentina Magri1, Luca Marino2,3, Francesco Del Giudice4
1Department of Pathology, Oncology and Radiology, Policlinico Umberto I Hospital, "Sapienza" University of Rome, 00161 Rome, Italy.
Biomedicines
|October 26, 2024
Summary
Enumerating tumor-derived extracellular vesicles (tdEVs) and circulating tumor cells (CTCs) in high-risk bladder cancer patients can improve prognosis prediction. Combining these biomarkers offers better risk stratification for non-muscle-invasive bladder cancer (NMIBC) progression.
Area of Science:
- Urology
- Oncology
- Biomarker Discovery
Background:
- Non-muscle-invasive bladder cancer (NMIBC) prognosis is variable due to heterogeneity.
- High-risk T1-G3 NMIBC, involving the lamina propria, has elevated recurrence, progression, and mortality rates.
Purpose of the Study:
- To evaluate tumor-derived extracellular vesicles (tdEVs) and circulating tumor cells (CTCs) in high-risk NMIBC patients.
- To correlate tdEV and CTC enumeration with survival outcomes like time to progression (TTP) and cancer-specific survival (CSS).
Main Methods:
- Analysis of 83 high-risk T1-G3 NMIBC patients treated between 2010-2013.
- Blood samples collected pre-transurethral resection of the bladder (TURB) analyzed using CellSearch® for CTCs.
- Automated tdEV evaluation using ACCEPT software with extended 120-month follow-up.
Main Results:
- Presence of at least one CTC correlated with shorter TTP and CSS.
- tdEV count demonstrated potential for additional patient risk stratification.
- Combined tdEVs and CTCs improved risk stratification for NMIBC progression.
Conclusions:
- tdEVs and CTCs are valuable biomarkers for prognosis and disease monitoring in high-risk NMIBC.
- Combining tdEVs and CTCs enhances risk stratification for NMIBC progression.
- Further research is needed to confirm findings and establish clinical significance in early-stage cancers.
